key: cord-0309470-g7lbf3j0
authors: Kilcoyne, A.; Jordan, E.; Zhou, A.; Thomas, K. A.; Pepper, A. N.; Chappell, D.; Amarapala, M.; Hughes, A.; Thompson, M.
title: Clinical Benefits and Budget Impact of Lenzilumab plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with COVID-19 in the United States from the Hospital Perspective
date: 2021-10-10
journal: nan
DOI: 10.1101/2021.10.06.21264651
sha: 1c662a156e3adf883a8fc60cef90cf5d0eadecf9
doc_id: 309470
cord_uid: g7lbf3j0

Aims: The study estimated the clinical benefits and budget impact of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the United States hospital perspective. Materials and Methods: An economic model was developed to estimate the clinical benefits and costs for an average newly hospitalized COVID-19 patient, with a 28-day time horizon for the index hospitalization. Clinical outcomes from the LIVE-AIR trial included failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included drug acquisition and administration for lenzilumab and hospital resource costs based on the level of care required. The inclusion of 1-year rehospitalization costs was examined in a scenario analysis. Results: In the base case and all scenarios, treatment with lenzilumab plus SOC improved all specified clinical outcomes over SOC alone. Adding lenzilumab to SOC was also estimated to result in cost savings of $3,190 per patient in a population aged <85 years with CRP <150 mg/L and receiving remdesivir (base case). Per-patient cost savings were also estimated in the following scenarios: 1) aged <85 years with CRP <150 mg/L, with or without remdesivir ($1,858); 2) Black and African American patients with CRP <150 mg/L ($13,154); and 3) Black and African American patients from the full population ($2,763). In the full mITT population, a budget impact of $4,952 was estimated. When adding rehospitalization costs to the index hospitalization, a total per-patient cost savings of $5,154 was estimated. Conclusions: The results highlight the clinical benefits for SWOV, ventilator use, time to recovery, mortality, time in ICU, and time on IMV, in addition to a favorable budget impact from the United States hospital perspective associated with adding lenzilumab to SOC for patients with COVID-19 pneumonia.

The coronavirus disease 2019 (COVID-19) pandemic has had a substantial cumulative societal and economic impact in the United States (US) and worldwide [1] [2] [3] . As of July 5, 2021, over 33 million cases and 603,000 deaths were reported in the US [4] . Data from the US Centers for Disease Control and Prevention (CDC) indicate that 8% of all individuals who developed COVID-19 between August 2020 and March 2021 required hospitalization [5] . Based on data from a large subset of US hospitals, 44 .6% of patients hospitalized with COVID-19 required intensive care unit (ICU) admission and 12.5% required invasive mechanical ventilation (IMV) over the same time period [6] .

The overall healthcare cost burden associated with the treatment of COVID-19 is substantial [7] [8] [9] . From the hospital perspective, providing care to patients with COVID-19 is associated with average per-patient costs ranging from a low of $14,325 USD for patients who do not require ICU admission to a high of $78,245 USD for patients who require both ICU admission and IMV [8] . Given the detrimental health outcomes and high economic burden among hospitalized patients with COVID-19, particularly those who require IMV, there remains a significant unmet need for safe, effective, and cost-effective treatment options [10] [11] [12] .

Many adverse clinical outcomes among patients with COVID-19 are the result of an immunopathological process called cytokine storm [13, 14] . This process is, in a significant part, mediated by granulocyte-macrophage colony-stimulating factor (GM-CSF), which activates and mobilizes myeloid cells, leading to dysregulated production of inflammatory cytokines and elevation of inflammatory markers (including C-reactive protein [CRP] ) [13, 15] . In patients with COVID-19, levels of GM-CSF-secreting T-cells and the extent of inflammatory cytokine production are directly correlated with lung tissue injury, disease severity, and ICU admission [14, [16] [17] [18] . Therefore, GM-CSF has been identified as an important therapeutic target in COVID-19 [18] .

Lenzilumab is a novel Humaneered ® anti-human GM-CSF monoclonal antibody that directly binds GM-CSF, thereby preventing its downstream signaling [13] . The Phase 3 LIVE-AIR trial (NCT04351152) is a randomized, double-blind, placebo-controlled study designed to evaluate early intervention with lenzilumab compared with placebo, both in combination with standard of care (SOC), in newly hospitalized patients with COVID-19 who have an oxygen saturation (SpO2) ≤94% on room air or require supplemental oxygen but have not progressed to IMV [13] .

Preliminary results of the LIVE-AIR trial showed that lenzilumab significantly improved the likelihood of achieving survival without ventilation (SWOV) 1 (sometimes referred to as ventilator-free survival) by day 28 compared with placebo [13] .

Lenzilumab plus SOC was most efficacious as measured by SWOV in the groups of patients aged <85 years with CRP levels <150 mg/L, and patients aged <85 years with CRP levels <150 mg/L receiving remdesivir, compared with SOC alone [13, 19] . Creactive protein is an important marker of systemic inflammation and elevated levels of CRP are associated with poor clinical outcomes among patients with severe COVID-19 [13, 20, 21] ; therefore, preliminary findings from the LIVE-AIR trial suggest that lenzilumab may be particularly effective when used as an early intervention in hospitalized patients. 1 SWOV is a robust composite endpoint used in many of the recent COVID-19 studies that is less prone to favor treatments with discordant effects on survival and days free of ventilation while avoiding the need for sample sizes approaching those of mortality trials to enable timely availability of study results.

Results from a post hoc analysis of the LIVE-AIR trial also suggest that Black and African American patients may exhibit the greatest response to lenzilumab, with a nearly 9-fold increase in SWOV among patients with CRP levels <150 mg/L [22] . This is notable as Black and African American persons have a 3-fold greater risk of hospitalization and 2-fold greater risk of death from COVID-19 [23] . The hypervulnerability in this population may be attributed to the low vaccination rates, the high prevalence of chronic illness (e.g., diabetes, hypertension, obesity), and the social determinants of health (e.g., socioeconomic status, healthcare access), all of which result in higher risk of infection, hospitalization, and death [23] [24] [25] [26] . Despite the disproportional incidence of COVID-19 in Black and African American persons, racial minority groups are typically underrepresented in COVID-19 clinical trials [27] .

However, Black and African Americans were well represented in LIVE-AIR, representing 14.8% of the trial population, which closely aligns with real-world demographics from the latest US Census (13.4%) [22, 28] .

Although clinical evidence indicates that lenzilumab is effective at improving SWOV in hospitalized patients with COVID-19 [13] , its overall clinical and economic value from the hospital decision maker perspective has not been previously characterized. The purpose of this study was to estimate the clinical benefits and budget impact of lenzilumab plus SOC compared with SOC alone in the treatment of hospitalized COVID-19 patients from the US hospital perspective.

An economic model was developed in Microsoft ® Excel to estimate the clinical benefits and budget impact of adding lenzilumab to SOC versus SOC alone for newly . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint hospitalized patients with COVID-19 pneumonia . The model was developed for a US   hospital perspective, with a 28-day time horizon for the index COVID-19 hospitalization (base case) and a 1-year time horizon for long-term costs (scenario). A 28-day time horizon for the index hospitalization was selected to align with data censoring in the LIVE-AIR trial (28 days following enrollment) [13] . A patient-level analysis was conducted to estimate the clinical benefits and costs for an average newly hospitalized patient with COVID-19 pneumonia. The model structure is presented in Adverse event (AE) management was not considered because the incidence of grade ≥3 AEs was similar in both arms of the LIVE-AIR trial (all differences for individual AEs between arms were less than 3%), and the lenzilumab arm had a lower overall incidence 2 Time to recovery was a pre-specified secondary outcome of the clinical trial and was defined as the first day on which a patient was discharged or ready for discharge by satisfying one of the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint of grade ≥3 AEs (26.7% versus 32.7% for the safety populations of the lenzilumab and placebo arms, respectively) [13] .

Based on a study by Di Fusco and colleagues [8] that examined the economic burden of hospitalized patients with COVID-19 in the US, patients were divided into four levels of care required: no ICU and no IMV, ICU but no IMV, IMV but no ICU, and both ICU and IMV. Hospital resource costs per patient were calculated as a weighted average based on the four levels of care required. First, the average time to recovery for each level of care was multiplied by the corresponding daily hospital resource use cost to obtain the average total hospital resource use cost for each level of care. Next, the weighted average cost per patient was calculated as the sum product of average total hospital resource use costs for each level of care and the corresponding proportion of patients requiring each level of care. These calculations were performed independently for the lenzilumab plus SOC and SOC alone arms to obtain separate weighted average costs for the two treatment options.

For long-term costs (scenario), only patients who survived the index hospitalization were eligible for rehospitalization. For IMV patients, this was calculated as the proportion with failure to achieve SWOV minus mortality after 28 days. For non-IMV patients, this was calculated as 100% minus the proportion with failure to achieve SWOV after 28 days.

Patient eligibility for the model was based on inclusion criteria for the LIVE-AIR trial. In brief, eligible patients were newly hospitalized with COVID-19 pneumonia, with SpO2 ≤94% on room air and/or requiring supplemental oxygen, but is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint not on IMV [13] . Data from the LIVE-AIR trial indicated that patients aged <85 years with CRP <150 mg/L particularly benefited from lenzilumab, and patients who received concomitant remdesivir also experienced greater benefit than patients who did not [13] .

Furthermore, US clinical practice guidelines recommend remdesivir for treatment of hospitalized patients with COVID-19 who require supplemental oxygen but not IMV [29] . Therefore, a population that only included patients aged <85 years with CRP <150 mg/L and who were receiving remdesivir was deemed the most informative for hospital decision makers and was selected for the base case. This base case population is also in line with the population being evaluated in the ongoing ACTIV-5/BET-B trial that aims to further elucidate the efficacy of lenzilumab in this patient population [30] . Scenario analyses were also conducted in patients aged <85 years with CRP <150 mg/L (with or without remdesivir) (scenario #1), in the full LIVE-AIR modified intent-to-treat (mITT) population 3 (scenario #2), in Black and African American patients with CRP <150 mg/L (with or without remdesivir) (scenario #3), and in Black and African American patients from the full mITT population (scenario #4). Data for the mITT population, the pre-specified primary analysis population, from the LIVE-AIR trial were used for all analyses [19] . 3 The mITT population was the analysis set used for the primary analysis of efficacy, defined as all randomized subjects who received at least one dose of study drug under the documented supervision of the principal investigator or sub-investigator and excluding sites that experienced documented limitations to access of basic supportive care for COVID-19. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint

Model inputs for treatment efficacy of lenzilumab plus SOC versus SOC alone were obtained from the LIVE-AIR trial [19] . Treatment efficacy inputs for the base case and scenario analyses are presented in Table 1 .

A targeted literature review was conducted to support parameterization of costing inputs informing the model. All costs were reported in 2021 USD, with adjustments for inflation made based on the US Bureau of Labor Statistics Consumer Price Index for medical care, when appropriate [31]. The drug acquisition cost for lenzilumab was a hypothetical $10,000 per patient for the entire treatment course [32] .

The treatment course for lenzilumab consisted of three 1-hour intravenous infusions, each administered 8 hours apart [13] . It was assumed that the cost to the hospital for each infusion was $34.87, for a total administration cost of $104.61. This cost was calculated based on the pharmacy labor and nonlabor (supplies) costs associated with administration of a monoclonal antibody over 60 minutes in a hospital-based setting, as reported by Schmier et al. [33] . Drug costs for SOC, including remdesivir and/or corticosteroids, were assumed to be captured in hospital resource use costs; they were not included as separate inputs in the model because it was assumed that lenzilumab would have no impact on the utilization or cost of background therapies. This assumption was supported by balanced remdesivir and corticosteroid use in both arms of the LIVE-AIR trial [13] .

Inputs for hospital resource use included the proportion of patients and time to recovery for each level of care informed by data from the LIVE-AIR trial [19] . Inputs is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ;  for daily hospital resource costs were obtained from the publication by Di Fusco et al. [8] by dividing the mean total hospital costs for each level of care by the corresponding mean length of stay. It was assumed that these daily costs incorporated all costs associated with SOC, including any remdesivir/corticosteroid use. Costs and resource use for each level of care are presented in Table 2 .

Rehospitalizations within one year of the index COVID-19 hospitalization were included in the model as long-term costs and explored in scenario analysis #5 (in additional to the index hospitalization). Given the paucity of rehospitalization data specific to COVID-19 pneumonia, it was assumed that rates from a study of acute respiratory distress syndrome (ARDS) patients by Wu et al. [34] could be used as a proxy. The study included ARDS patients who received mechanical ventilation in their index hospitalization and non-ARDS hospitalized controls [34] . Thus, it was assumed that ARDS and non-ARDS patients from the study represented IMV and non-IMV patients in the model, respectively. Based on the study by Wu et al. [34] , a rehospitalization rate of 53.2% was assumed for surviving IMV patients and 12.9% for non-IMV patients.

Rehospitalization costs were also derived from Wu et al. [34] , with the assumption that not all of the annual long-term costs for healthcare resource use reported in the study were associated with rehospitalization. Based on a study of acute lung injury survivors by Ruhl et al. [35] , it was assumed that 76% of the annual costs from Wu et al. [34] were from hospital readmissions. Therefore, it was assumed that if a patient was rehospitalized within one year of the index hospitalization, the cost would be $77,502 and $21,232 for IMV and non-IMV patients, respectively, after adjusting for inflation. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint

As mentioned previously, the base case analysis included patients aged <85 years with CRP <150 mg/L, and who were receiving remdesivir. Two scenario analyses were conducted to examine the budget impact of lenzilumab in broader patient populations. Scenario analysis #1 included patients aged <85 years with CRP <150 mg/L, with or without remdesivir. The full LIVE-AIR mITT population was included in scenario analysis #2. Two scenario analyses were also conducted to examine the budget impact in narrower patient populations. Scenario analysis #3 included Black and African American patients with CRP <150 mg/L, with or without remdesivir. Black and African American patients from the full mITT population were included in scenario analysis #4. Lastly, scenario analysis #5 added rehospitalization costs to the base case analysis to evaluate the combined budget impact to the hospital for the index hospitalization and estimated one-year long-term care costs.

Sensitivity analyses were conducted to determine the key budget impact drivers of the model. The following model inputs were included for sensitivity analyses: daily hospital costs, patient distributions in each level of care (lenzilumab plus SOC arm only), and time to recovery (lenzilumab plus SOC arm only). Inputs were adjusted by ±10%. Daily hospital costs for each level of care were adjusted simultaneously, as were time to recovery inputs. For patient distributions, the proportion of patients requiring both ICU and IMV was adjusted first and then the three other levels of care were reweighted, maintaining the proportionality between the levels of care prior to adjustment. The decision to use the ICU and IMV group for adjustment in the sensitivity analysis was based on the assumption that this group was the largest driver of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ;  costs in the model, as a result of the increased cost of care per day and the longer length of stay.

In the base case and all scenario analyses, treatment with lenzilumab plus SOC improved all specified clinical outcomes over SOC alone ( Table 3 In addition to improved clinical outcomes, adding lenzilumab to SOC was also estimated to produce cost savings of $3,190 per patient in the base case analysis ( Table 4 ). Scenario analysis #1 (aged <85 years with CRP <150 mg/L, with or without remdesivir) also estimated cost savings of $1,858 per patient. In scenario analysis #2 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; remdesivir) and scenario analysis #4 (Black and African American patients from the full mITT population) estimated cost savings of $13,154 and $2,763 per patient, respectively. In addition to the index hospitalization, rehospitalization costs were included for scenario analysis #5 (with base case parameters for all other inputs); the addition of rehospitalization costs yielded further cost savings of $1,964 per patient in addition to the base case ($3,190), for total per patient cost savings of $5,154.

Inputs for hospital resource costs, patient distributions, and time to recovery were adjusted by ±10% (with base case parameters for all other inputs) in sensitivity analyses to determine the key budget impact model drivers. While all sensitivity analyses resulted in cost savings for lenzilumab plus SOC compared with SOC alone, there was variability relative to the base case results ( Table 5) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint

The present analysis evaluated the clinical benefits and budget impact of adding lenzilumab to SOC for the treatment of COVID-19 pneumonia from a US hospital perspective. The overall goal was to provide evidence that may assist hospital decision makers considering the use of lenzilumab as an option in the treatment of this condition that urgently requires new efficacious therapies.

Addition of lenzilumab to SOC was found to improve all specified clinical outcomes in the base case and scenario analyses, including SWOV, mortality, time to recovery, ICU use, and IMV use. SWOV is an important outcome among patients with COVID-19 from the hospital perspective, as avoiding IMV greatly reduces the average length of a patient's hospital stay [36] . For all five analysis populations explored from the LIVE-AIR trial, the average time to recovery for patients with IMV was more than double that of patients without IMV [19] . In the present analysis, addition of lenzilumab to SOC resulted in a 15.5% absolute reduction in the probability of requiring IMV compared with SOC alone among patients aged <85 years with CRP <150 mg/L who were receiving remdesivir. The average number of bed days, ICU days, and IMV days were also reduced among patients who received lenzilumab in this patient population.

Further, the NNT findings showed that every sixth patient avoided IMV or death if the cohort was treated with lenzilumab plus SOC rather than SOC alone. Lenzilumab also provided a benefit in terms of mortality, with an NNT of 10 to save one life. Therefore, for every 100 patients in this population, the results of this analysis suggest that 10 lives could be saved by treating with lenzilumab plus SOC in place of SOC alone.

Lenzilumab was also associated with a favorable budget impact from the hospital perspective in the base case analysis. Although the addition of lenzilumab to SOC was associated with increases in drug acquisition and administration costs is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ;  compared with SOC alone, these additional costs were more than offset by the reduction in costs for hospital resource use among patients treated with lenzilumab. This led to a net per-patient cost savings of $3,190 with lenzilumab plus SOC compared with SOC alone among patients aged <85 years with CRP <150 mg/L who were receiving remdesivir.

In all scenario analyses conducted in both broader and narrower patient populations than that used for the base case analysis, addition of lenzilumab to SOC In terms of budget impact, the addition of lenzilumab to SOC among patients aged <85 years with CRP <150 mg/L with or without concomitant remdesivir was still associated with a cost savings of $1,858, although this was smaller than the net savings in the base case population. When assessed in the full LIVE-AIR mITT population, the budget impact of adding lenzilumab to SOC was $4,952 per patient. Taken together, the results of these analyses show that adding lenzilumab to SOC for patients aged <85 years with CRP <150 mg/L, regardless of remdesivir use, may provide clinical and economic benefits for US hospitals. In a broader population of patients with COVID-19 pneumonia without consideration of age or CRP criteria, adding lenzilumab to SOC also improved clinical outcomes but with an increased budget impact. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint Among patients hospitalized with COVID-19, elevated levels of CRP at the time of admission are positively correlated with disease severity and are associated with adverse clinical outcomes [13, 20, 21, 37, 38] . Further, CRP levels >100 mg/L at the time of admission are among the strongest independent predictors of critical illness [20, 21] , and patients with CRP levels >150 mg/L are considered at high risk for escalation of respiratory support (i.e., need for non-invasive ventilation or intubation) or death [39] .

Given that lenzilumab resulted in particularly favorable clinical outcomes and cost savings among patients aged <85 years with CRP levels <150 mg/L, irrespective of whether all patients were receiving remdesivir, it appears to be most effective and provide the best economic value when used as an early intervention. Since testing for CRP levels is widely accessible and inexpensive in the US hospital setting [40] , it may be a valuable and feasible approach to identify patients hospitalized with COVID-19 who may benefit most from treatment with lenzilumab.

Despite the Black and African American population being disproportionately affected by COVID-19, clinical trials frequently underrepresent this population [23] . As a result, there is a gap in knowledge regarding differences in disease severity, outcomes, and treatments across racial populations [27] . Results from a retrospective analysis of the LIVE-AIR trial suggest that Black and African American patients, in particular those with a CRP level <150 mg/L, demonstrate the greatest response to lenzilumab is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint African American patients within the clinical trial is proportional to the US ethnic distribution and thus, were well represented in the study overall [22, 28] .

Notably, the long-term health impacts of COVID-19 are not well characterized because of the novelty of the disease. However, the US CDC is monitoring several post-COVID conditions that may persist for weeks or months after initial infection and may impact most or all body systems [41] . Further, evidence from other recent outbreaks of conditions caused by similar coronaviruses, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), suggests that adverse respiratory, cardiovascular, and mental health outcomes may persist for months or years after resolution of the initial disease [42] [43] [44] [45] [46] . In terms of the present study, research into the long-term impact of COVID-19 would provide greater accuracy in the model's budget impact estimations by reducing the number of assumptions required for rehospitalization costs. Despite these limitations, a scenario analysis was conducted to assess potential long-term cost savings with lenzilumab by incorporating rehospitalizations over one year after initial hospitalization into the analysis. The results indicated that adding lenzilumab to SOC may result in total cost savings of $5,154 associated with reduction in IMV use during the index hospitalization.

The sensitivity analyses suggested that model results were robust to changes reflecting a reasonable level of uncertainty (±10%) in key inputs including hospital resource costs, patient distributions to different levels of care, and time to recovery. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint As with any model-based analysis, this study had several limitations. The analysis used data from the LIVE-AIR Phase 3 clinical trial, which would not be fully generalizable to a real-world US hospital population. Patient data from LIVE-AIR were censored after 28 days following trial enrollment. This is noteworthy because patients with COVID-19 who are critically ill and/or who require IMV typically have extended time to recovery, sometimes beyond 28 days [21, 47, 48] . Therefore, the model may underestimate time to recovery for patients who require IMV by only allowing up to 28 days of hospital resource use. Consequently, cost savings associated with the reduction in proportion of patients who require IMV may be even greater than suggested by the results of the current analysis. Finally, while the US Food and Drug Administration (FDA) recently (September 9 th , 2021) declined the request for emergency use authorization (EUA) of lenzilumab to treat newly hospitalized COVID-19 patients based on the data from the LIVE-AIR trial concluding additional clinical data are required [49] , the FDA has invited Humanigen to submit any supplemental data as they become available. It is also anticipated that the ongoing ACTIV-5/BET-B trial, which has been advanced to enroll up to 550 patients, may provide additional efficacy and safety data sufficient to further support the use of lenzilumab for the treatment of hospitalized COVID-19 patients [30] .

Overall, the results of this analysis highlight the clinical benefits for SWOV, ventilator use, time to recovery, mortality, time in ICU, and time on IMV, in addition to a favorable budget impact from the US hospital perspective associated with adding lenzilumab to SOC for patients with COVID-19 pneumonia. Lenzilumab provides clinical benefits to a broad population of patients with characteristics similar to the full study cohort from the LIVE-AIR trial. Notably, the drug appears to be particularly effective in patients aged <85 years with CRP <150 mg/L and it is estimated to result in . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ;  cost savings to US hospitals when used in this patient population. These clinical benefits and cost savings extend to the Black and African American subgroup as well.

This is a critical finding as Black and African American persons are hyper-vulnerable to COVID-19 [23] . Concomitant use of remdesivir with lenzilumab further improves clinical benefits and cost savings. These findings support the use of lenzilumab as a standard option in the treatment of COVID-19 pneumonia and may help to assist hospital formulary decision makers with their consideration regarding its adoption in the hospital setting should an EUA or full approval through a Biologics License Application be granted.

This work was supported by Humanigen Inc. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; Abbreviations. CRP, C-reactive protein; ICU, intensive care unit; IMV, invasive mechanical ventilation; mITT, modified intent-to-treat; SOC, standard of care; SWOV, survival without ventilation. a All data were censored at 28 days following trial enrollment. Data are presented for the mITT population. b These values were dervied from Kaplan-Meier analysis.

Abbreviations. N/A, not applicable; SOC, standard of care. * It was assumed that use of SOC drugs would not be affected by the concomitant use of lenzilumab, resulting in no cost differences for SOC drugs between both groups. This assumption was supported by the balanced use of remdesivir and corticosteroids in both treatment arms of the LIVE-AIR trial [13] . ** Rehospitalization costs are optional in the model. They were not included in the base case analysis but were included for scenario analysis #5.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 10, 2021. ; https://doi.org/10.1101/2021.10.06.21264651 doi: medRxiv preprint

Global assessment of environment, health and economic impact of the novel coronavirus (COVID-19). Environ Dev Sustain

Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Practice & Research Clinical Anaesthesiology

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

Centers for Disease Control and Prevention: COVID Data Tracker United States COVID-19 Cases, Deaths, and Laboratory Testing (NAATs) by State, Territory, and Jurisdiction [Internet

Centers for Disease Control and Prevention: COVID Data Tracker United States -New Admissions of Patients with Confirmed COVID-19

Centers for Disease Control and Prevention: COVID Data Tracker United States -COVID-19 Hospitalizations and Disease Severity

Potential costs of COVID-19 treatment for people with employer coverage

Health outcomes and economic burden of hospitalized COVID-19 patients in the United States

Centers for Medicare & Medicaid Services. COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing

A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States

Baricitinib Therapy in Covid-19 Pneumonia -An Unmet Need Fulfilled

Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects [Review]. Frontiers in Immunology

Lenzilumab Efficacy and Safety in Newly Hospitalized Covid-19 Subjects: Results from the Live-Air Phase 3

Randomized Double-Blind Placebo-Controlled Trial. medRxiv

Characteristics of SARS-CoV-2 and COVID-19

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients

Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Additional data analyses for LIVE-AIR Phase 3 randomized double-blind placebo-controlled trial. Data on file

Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care

Humanigen: Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients

Risk for COVID-19 Infection, Hospitalization, and Death by Race/Ethnicity

S: Latest Data on COVID-19 Vaccinations by Race/Ethnicity

Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry

Racial Disproportionality in Covid Clinical Trials

National Institutes of Health: COVID-19 Treatment Guidelines -Therapeutic Management of Hospitalized Adults with COVID-19

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

Bureau of Labor Statistics: CPI-All Urban Consumers (Current Series); Medical care in U.S. city average, all urban consumers, not seasonally adjusted

Lenzilumab drug cost. Data on file

Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting

Healthcare costs utilization and costs of patients hospitalized with acute respiratory distress syndrome (ARDS) in US commercially-insured individuals and Medicare beneficiaries

Health care resource use and costs of twoyear survivors of acute lung injury. An observational cohort study

Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach

Prognostic Value of C-Reactive Protein in Patients With Coronavirus

Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19

COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19

Centers for Disease Control and Prevention: Post-COVID Conditions

Short-and potential long-term adverse health outcomes of COVID-19: a rapid review

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up

Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. Sci Rep

Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure

ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease

Humanigen: FDA has declined Humanigen's Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients

The authors acknowledge Cameron Durant (Humanigen Inc.), Ari Mendell (EVERSANA), and Karson Theriault (EVERSANA) for their specific contributions to this project.

Abbreviations. CRP, C-reactive protein; ICU, intensive care unit; IMV, invasive mechanical ventilation; mITT, modified intent-to-treat; NNT, number needed to treat; SOC, standard of care; SWOV, survival without ventilation. a These values were dervied from Kaplan-Meier analysis. Abbreviations. CRP, C-reactive protein; mITT, modified intent-to-treat; SOC, standard of care. a Negative numbers indicate a net cost savings with lenzilumab, whereas postive numbers indicate a net budget impact with lenzilumab.